AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27171984 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with vincristine, prednisone, doxorubicin, and pegylated asparaginase; Imatinib for Philadelphia chromosome-positive disease; followed by consolidation with clofarabine.
Number of subjects: 30
Study 27171984 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT) after induction and consolidation I.
Number of subjects: 30
Study 27171984 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) at 1 year.
Number of subjects: 30
Study 27171984 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) at 2 years.
Number of subjects: 30
Study 27171984 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival (DFS) at 2 years for patients achieving CR.
Number of subjects: 30
Study 27172991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sloped shoulder configuration implants
Number of subjects: 184
Study 27174159 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone (DRSP)/estradiol
Number of subjects: 30597
Study 27174159 — intervention group
Group type: COMPARATOR
Intervention: Other oral continuous combined HRT (HRTcc)
Number of subjects: 30597
Study 27174882 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27174885 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI ventilation defects (quantified using VDP)
Number of subjects: 18
Study 27174885 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI (Lung Clearance Index)
Number of subjects: 18
Study 27174885 — intervention group
Group type: EXPERIMENTAL
Intervention: ACQ (Asthma Control Questionnaire)
Number of subjects: 18
Study 27174885 — intervention group
Group type: EXPERIMENTAL
Intervention: AQLQ (Asthma Quality of Life Questionnaire)
Number of subjects: 18
Study 27175116 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 160/80 mg
Number of subjects: 30
Study 27175116 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 80/40 mg
Number of subjects: 30
Study 27175292 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) + Methotrexate (MTX) combination therapy
Number of subjects: 0
Study 27175292 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 0
Study 27175291 — intervention group
Group type: EXPERIMENTAL
Intervention: EASY model (group-based education, individualized physical activity prescription, Fitbit monitor)
Number of subjects: 25
Study 27175291 — intervention group
Group type: COMPARATOR
Intervention: Control group (health-related information only)
Number of subjects: 25
Study 27175285 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care (n=59)
Number of subjects: 115
Study 27175285 — intervention group
Group type: COMPARATOR
Intervention: Self-management (n=56)
Number of subjects: 115
Study 27175296 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 or 10 mg twice daily
Number of subjects: 956
Study 27175296 — intervention group
Group type: COMPARATOR
Intervention: MTX titrated to 20 mg/week
Number of subjects: 956
Study 27175297 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 89
Study 27175297 — intervention group
Group type: COMPARATOR
Intervention: PDUS
Number of subjects: 89
Study 27175553 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D concentration (mean total 25-OHD concentration 32.2 nmol/l, range 21.8-46.6 nmol/l)
Number of subjects: 92
Study 27175553 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity assessment using two-step euglycaemic hyperinsulinaemic clamp and HOMA2-IR
Number of subjects: 92
Study 27175553 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-cell function assessment using HOMA2%B
Number of subjects: 92
Study 27175553 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition assessment using DEXA
Number of subjects: 92
Study 27176479 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal MRI scans including structural MRI (sMRI), resting state functional MRI (rs-fMRI), diffusion tensor imaging (DTI)
Number of subjects: 200
Study 27176479 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation including WHO-UCLA AVLT, ACE-R, MMSE, MoCA, CDR
Number of subjects: 200
Study 27176617 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke-specific, cerebrovascular and neurodegenerative, inflammatory, endothelial, and (epi)genetic markers
Number of subjects: 250
Study 27176617 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric and neurocognitive assessments
Number of subjects: 250
Study 27176617 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers from blood and MRI scans
Number of subjects: 250
Study 27176617 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up data
Number of subjects: 250
Study 27177028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI)
Number of subjects: 303
Study 27177028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-ankle vascular index (CAVI)
Number of subjects: 303
Study 27177028 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial-ankle pulse wave velocity (ba-PWV)
Number of subjects: 303
Study 27177028 — intervention group
Group type: EXPERIMENTAL
Intervention: Central augmentation index (AIx_75)
Number of subjects: 303
Study 27177028 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQL) measurements (SF-12)
Number of subjects: 303
Study 27177177 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC) with radiation therapy (RT) and temozolomide (TMZ)
Number of subjects: 0
Study 27177860 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m² intravenously on days 1 and 8 every 21 days
Number of subjects: 1644
Study 27177860 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice after 2-5 prior chemotherapies
Number of subjects: 1644
Study 27177929 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 12 weeks: five times a week for 4 weeks followed by three times a week for 8 weeks.
Number of subjects: 21
Study 27178240 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy (20, 50, 100, 200, 400 mg ramp-up to 400 mg daily)
Number of subjects: 107
Study 27178240 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy
Number of subjects: 107
Study 27178625 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) group
Number of subjects: 1311
Study 27178625 — intervention group
Group type: COMPARATOR
Intervention: Non-OSA group
Number of subjects: 1311
Study 27178625 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA
Number of subjects: 1311
Study 27178705 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF 5-methyltetrahydrofolate (5-MTHF) levels at time 1
Number of subjects: 67
Study 27178705 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF 5-methyltetrahydrofolate (5-MTHF) levels at follow-up
Number of subjects: 67
Study 27178705 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between time 1 and time 2 CSF 5-MTHF measurements
Number of subjects: 67
Study 27178705 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF 5-MTHF levels and clinical features of autism
Number of subjects: 67
Study 27178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 85
Study 27178765 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 85
Study 27178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment program (MTP)
Number of subjects: 85
Study 27179604 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma treatment (specifics not provided)
Number of subjects: 8111
Study 27180047 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART study of antipsychotic medications
Number of subjects: 48
Study 27180047 — intervention group
Group type: COMPARATOR
Intervention: Traditional randomized clinical trials (RCTs)
Number of subjects: 48
Study 27181924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian tissue cryopreservation (OTCP) and transplantation, endocrine monitoring, in vitro fertilization (IVF)
Number of subjects: 20
Study 27181924 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF treatments
Number of subjects: 20
Study 27181924 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF and spontaneous conception
Number of subjects: 20
Study 27182277 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 16
Study 27182277 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Number of subjects: 16
Study 27182277 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 16
Study 27182626 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27182836 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Other (SO) intervention
Number of subjects: 369
Study 27184359 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis
Number of subjects: 434
Study 27184359 — intervention group
Group type: COMPARATOR
Intervention: BMI cut points
Number of subjects: 434
Study 27184359 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and sex-specific regression parameters
Number of subjects: 434
Study 27184359 — intervention group
Group type: EXPERIMENTAL
Intervention: %BF classification
Number of subjects: 434
Study 27185573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalotuzumab monotherapy at 900 mg/m2
Number of subjects: 24
Study 27185573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalotuzumab monotherapy at 1200 mg/m2
Number of subjects: 24
Study 27185573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalotuzumab monotherapy at 1500 mg/m2
Number of subjects: 24
Study 27185573 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of dalotuzumab and ridaforolimus (28 mg/m2 daily for days 1-5, repeated weekly)
Number of subjects: 24
Study 27185573 — intervention group
Group type: COMPARATOR
Intervention: Dalotuzumab monotherapy
Number of subjects: 24
Study 27185670 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (R+) anesthesia
Number of subjects: 317
Study 27185670 — intervention group
Group type: COMPARATOR
Intervention: Nonremifentanil (R-) anesthesia
Number of subjects: 317
Study 27185799 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (Cresemba); pharmacokinetic analysis based on a 2-compartment model with first-order absorption.
Number of subjects: 136
Study 27185799 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (Cresemba); pharmacokinetic parameters compared across different IFD groups.
Number of subjects: 136
Study 27185799 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (Cresemba); impact of covariates on pharmacokinetics.
Number of subjects: 136
Study 27185808 — intervention group
Group type: COMPARATOR
Intervention: Tedizolid phosphate (single intravenous dose)
Number of subjects: 18
Study 27186579 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir/Peginterferon/Ribavirin (SMV/PR)
Number of subjects: 534
Study 27187303 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping PPIs for 2 weeks
Number of subjects: 12
Study 27187854 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)
Number of subjects: 896
Study 27187983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nav-6 filter
Number of subjects: 141
Study 27187983 — intervention group
Group type: COMPARATOR
Intervention: No filter
Number of subjects: 141
Study 27188189 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-team residents
Number of subjects: 257
Study 27188189 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan complexity
Number of subjects: 257
Study 27188189 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 257
Study 27188189 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental education
Number of subjects: 257
Study 27188262 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically-induced weight loss (SG and RYGB)
Number of subjects: 137
Study 27188262 — intervention group
Group type: COMPARATOR
Intervention: Conventional dietary treatment (CDT)
Number of subjects: 137
Study 27188262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 137
Study 27188262 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 137
Study 27188262 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL)
Number of subjects: 137
Study 27188270 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 2-4mg
Number of subjects: 0
Study 27188270 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 0
Study 27188804 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine (MF) for 12 weeks at an allometric dose
Number of subjects: 80
Study 27188960 — intervention group
Group type: EXPERIMENTAL
Intervention: daclatasvir + sofosbuvir for 12 weeks
Number of subjects: 0
Study 27188960 — intervention group
Group type: EXPERIMENTAL
Intervention: daclatasvir + sofosbuvir
Number of subjects: 0
Study 27189066 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with diabetes (prevalent diabetes)
Number of subjects: 1034074
Study 27189066 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with incident diabetes
Number of subjects: 1034074
Study 27189066 — intervention group
Group type: COMPARATOR
Intervention: Men without diabetes
Number of subjects: 1034074
Study 27189142 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet support group
Number of subjects: 863
Study 27189142 — intervention group
Group type: COMPARATOR
Intervention: Online expressive writing
Number of subjects: 863
Study 27189422 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders only
Number of subjects: 0
Study 27189422 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders and a 75 KES incentive
Number of subjects: 0
Study 27189422 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders and a 200 KES incentive
Number of subjects: 0
Study 27189422 — intervention group
Group type: COMPARATOR
Intervention: No intervention (general health-related text message)
Number of subjects: 0
Study 27189815 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvolt T-wave alternans and 24-hour Holter monitoring
Number of subjects: 253
Study 27189815 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP (≥1,600 pg/ml)
Number of subjects: 253
Study 27189815 — intervention group
Group type: EXPERIMENTAL
Intervention: VPC number
Number of subjects: 253
Study 27189954 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint pacing (MPP) programmed to 'ON' (n = 94)
Number of subjects: 507
Study 27189954 — intervention group
Group type: COMPARATOR
Intervention: Control group (MPP programmed to 'OFF', n = 138)
Number of subjects: 507
Study 27189954 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint pacing (MPP)
Number of subjects: 507
Study 27189954 — intervention group
Group type: COMPARATOR
Intervention: Optimal MPP vs. conventional vectors
Number of subjects: 507
Study 27190094 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMS 2G drug-eluting absorbable metal scaffold
Number of subjects: 123
Study 27190101 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter heart valve (THV)
Number of subjects: 1661
Study 27190628 — intervention group
Group type: EXPERIMENTAL
Intervention: Indium (In-111) labeled T-cells
Number of subjects: 1
Study 27190628 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent PET-CT imaging
Number of subjects: 1
Study 27190628 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell therapy
Number of subjects: 1
Study 27192671 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 800 mg per day for 24 months
Number of subjects: 27
Study 27193036 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegethon mobile app (self-monitoring of vegetable consumption, goal setting, feedback, social comparison)
Number of subjects: 17
Study 27193036 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegethon mobile app
Number of subjects: 17
Study 27193308 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluvia paclitaxel-eluting stent
Number of subjects: 57
Study 27193580 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR MAMA program (DPP-based intervention)
Number of subjects: 22
Study 27193584 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27194306 — intervention group
Group type: EXPERIMENTAL
Intervention: Total barriers to meeting DGA
Number of subjects: 836
Study 27194306 — intervention group
Group type: EXPERIMENTAL
Intervention: Total facilitators to meeting DGA
Number of subjects: 836
Study 27194306 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPyramid components barriers
Number of subjects: 836
Study 27194306 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPyramid components facilitators
Number of subjects: 836
Study 27194306 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to meeting recommendations for meats and beans; solid fats, alcohol, and added sugars; and physical activity
Number of subjects: 836
Study 27194306 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver facilitators
Number of subjects: 836
Study 27195129 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation capsule colonoscopy (CC2)
Number of subjects: 51
Study 27195129 — intervention group
Group type: COMPARATOR
Intervention: Magnesium citrate as a boost agent
Number of subjects: 51
Study 27195659 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Number of subjects: 0
Study 27195659 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 0
Study 27195659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with pomalidomide and dexamethasone
Number of subjects: 0
Study 27195659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with lenalidomide and dexamethasone
Number of subjects: 0
Study 27196139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 9
Study 27196293 — intervention group
Group type: EXPERIMENTAL
Intervention: GCSB-5
Number of subjects: 761
Study 27196358 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC4D smartphone application used for 6 weeks
Number of subjects: 10
Study 27196576 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI-assisted optical diagnosis
Number of subjects: 1688
Study 27196589 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose regimen
Number of subjects: 1447
Study 27196589 — intervention group
Group type: COMPARATOR
Intervention: Day-before regimen
Number of subjects: 1447
Study 27196589 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose uptake based on appointment time
Number of subjects: 1447
Study 27197177 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched therapy (N = 122/188, 65%)
Number of subjects: 500
Study 27197177 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmatched therapy (N = 66/188, 35%)
Number of subjects: 500
Study 27197177 — intervention group
Group type: EXPERIMENTAL
Intervention: High matching scores
Number of subjects: 500
Study 27197299 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AMH concentrations
Number of subjects: 172
Study 27197299 — intervention group
Group type: COMPARATOR
Intervention: Early life BMI and current adult BMI
Number of subjects: 172
Study 27197604 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT
Number of subjects: 0
Study 27197604 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-primaquine
Number of subjects: 0
Study 27198664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir fixed-dose combination tablet for 12 weeks
Number of subjects: 93
Study 27198680 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES) implantation for ULMD
Number of subjects: 393
Study 27198948 — intervention group
Group type: COMPARATOR
Intervention: No-OSA, mild-moderate and severe OSA cases (stratified according to the apnea-hypopnea index)
Number of subjects: 825
Study 27198948 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 825
Study 27198948 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytic treatment
Number of subjects: 825
Study 27198948 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 825
Study 27198947 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 600 mg
Number of subjects: 309
Study 27198947 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 1200 mg
Number of subjects: 309
Study 27198947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 27199429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3BNC117 infusion
Number of subjects: 0
Study 27199429 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study 27199777 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaming platform intervention for Autism
Number of subjects: 10
Study 27199864 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based family intervention using cooking and dining as a platform, covering themes of joy, gratitude, flow, savoring, and listening.
Number of subjects: 2070
Study 27199864 — intervention group
Group type: EXPERIMENTAL
Intervention: Savoring intervention (one of the five themes).
Number of subjects: 2070
Study 27199864 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 2070
Study 27199889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment with five consecutive days of 2 mA cathodal tDCS over M1 for 20 min
Number of subjects: 22
Study 27199889 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic treatment plus sham tDCS
Number of subjects: 22
Study 27203140 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical clipping (MC)
Number of subjects: 99
Study 27203140 — intervention group
Group type: COMPARATOR
Intervention: Endovascular coiling (EC)
Number of subjects: 99
Study 27203778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineered human acellular vessel implantation
Number of subjects: 60
Study 27206463 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV Self-Management Program
Number of subjects: 134
Study 27206463 — intervention group
Group type: COMPARATOR
Intervention: Information-only
Number of subjects: 134